The Ludwig Institute for Cancer Research Ltd is a global not-revenue driven association with a 40-year legacy of spearheading malignancy disclosures. The Institute gives its researchers from as far and wide as possible with the assets and the adaptability to understand the all-around beneficial capability of their work and see their disclosures progress human well-being. This reasoning, joined with strong translational projects, amplifies the capability of achievement revelations to be more alluring for business improvement. The Ludwig Institute directs it examine and clinical trials, making it an extension from the most fundamental inquiries of life to the most pressing needs of disease consideration. Since its commencement, the Institute has contributed more than $1.7 billion of its own assets in disease research, and has a gift esteemed at $1.2 billion. The Institutes benefits are overseen by the LICR Fund. Ludwig Cancer Research is a worldwide group of recognized researchers committed to forestalling and controlling tumour. American Business-man Daniel K. Ludwig started to help disease research with the station of the Ludwig Institute for Cancer Research in 1971. Today, the logical deliberations enriched through his assets have developed to incorporate the Ludwig Institute and the Ludwig Centres at six U.S. establishments, all seeking after leaps forward to change the course of tumour.
The following is the list of scholars from Ludwig Institute for Cancer Research who contributed and/or serves as editors for one or more OMICS International journals and conferences
The following is the list of proceedings by scholars from Ludwig Institute for Cancer Research that are published in OMICS International journals and conferences.
Vasileios Atsaves, Emmanouel Simantirakis, Ioannis Tsironis, Steven M Dunn and George Vassilopoulos